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Abstract
Background: High alcohol consumption is a major cause of morbidity, yet alcohol is
associated with both favourable and adverse effects on cardiometabolic risk markers.
We aimed to characterize the associations of usual alcohol consumption with a compre-
hensive systemic metabolite profile in young adults.
Methods: Cross-sectional associations of alcohol intake with 86 metabolic measures
were assessed for 9778 individuals from three population-based cohorts from Finland
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(age 24–45 years, 52% women). Metabolic changes associated with change in alcohol in-
take during 6-year follow-up were further examined for 1466 individuals. Alcohol intake
was assessed by questionnaires. Circulating lipids, fatty acids and metabolites were
quantified by high-throughput nuclear magnetic resonance metabolomics and biochem-
ical assays.
Results: Increased alcohol intake was associated with cardiometabolic risk markers
across multiple metabolic pathways, including higher lipid concentrations in HDL sub-
classes and smaller LDL particle size, increased proportions of monounsaturated fatty
acids and decreased proportion of omega-6 fatty acids, lower concentrations of glutam-
ine and citrate (P<0.001 for 56 metabolic measures). Many metabolic biomarkers dis-
played U-shaped associations with alcohol consumption. Results were coherent for men
and women, consistent across the three cohorts and similar if adjusting for body mass
index, smoking and physical activity. The metabolic changes accompanying change in al-
cohol intake during follow-up resembled the cross-sectional association pattern
(R2¼0.83, slope¼0.7260.04).
Conclusions: Alcohol consumption is associated with a complex metabolic signature,
including aberrations in multiple biomarkers for elevated cardiometabolic risk. The meta-
bolic signature tracks with long-term changes in alcohol consumption. These results elu-
cidate the double-edged effects of alcohol on cardiovascular risk.
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Introduction
Alcohol consumption is one of the leading risk factors for
death and disability, accounting for almost 3 million annual
deaths globally and 3.9% of life-years lost to disease.1 The
harmful effects of alcohol use are well characterized and un-
contentious for some conditions, such as liver cirrhosis,
injuries and several cancers.1,2 However, considerable debate
remains as to the nature of the association between the
amount of alcohol consumed and cardiovascular disease.3–5
Observational studies have generally found a U-shaped rela-
tionship between alcohol intake and cardiovascular disease
risk, with lower risk in moderate drinkers compared with
Key Messages
• Alcohol consumption in young adults is associated with a complex metabolic signature, comprising both favourable
and adverse effects in relation to the risk of cardiovascular disease and type 2 diabetes. Multiple novel cardiometa-
bolic biomarkers were adversely associated with alcohol intake.
• Prominent metabolic associations with alcohol consumption include monounsaturated fatty acids, omega-6 fatty
acids, glutamine, citrate and lipoprotein particle size. Many of these cardiometabolic biomarkers were as strongly
associated with alcohol intake as HDL cholesterol. Most lipid measures displayed U-shaped associations with alcohol
consumption, whereas the strongest novel biomarkers of alcohol intake followed linear association shapes.
• The large sample size provides robust evidence for many novel metabolic markers of alcohol consumption, in par-
ticular since results were coherent across the three cohorts despite differences between the measures of alcohol
intake.
• Long-term changes in alcohol intake were associated with a pattern of metabolic changes similar to the metabolic
signature of alcohol observed cross-sectionally. The tracking of the comprehensive metabolic signature of alcohol
consumption suggest that the metabolic changes arise, at least partly, due to alcohol consumption.
• The results provide improved understanding of the diverse molecular processes related to alcohol intake. Novel sys-
temic biomarkers reflecting both alcohol intake and cardiovascular risk could serve as molecular intermediates and
may therefore help to bridge the complex relation between alcohol and cardiometabolic risk.
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both abstainers and heavier drinkers.3 Whether this effect is
causal or due to confounding remains an unresolved issue. A
recent Mendelian randomization study on ADH1B1 sug-
gested adverse effects of any amount of alcohol on coronary
heart disease.5 Interventional studies on the effects of alcohol
on circulating risk markers have indicated favourable effects
on adiponectin, fibrinogen and high-density lipoprotein
(HDL) cholesterol,6,7 and the causal effect of alcohol on the
latter has been supported by Mendelian randomization stud-
ies on ALDH2.8,9 However, accumulating evidence suggests
that these markers are not causally related to cardiometa-
bolic risk,10–13 and the apparent cardioprotective role of
modest alcohol consumption may therefore not be ascribed
to mediation through these measures. Novel systemic bio-
markers reflecting both alcohol intake and cardiovascular
risk could serve as molecular intermediates to bridge the in-
tricate exposure-disease relation.
The physiological effects of alcohol involve multiple
metabolic pathways that extend beyond routine risk
markers.14–17 Metabolomics provides a fine-grained snap-
shot of systemic metabolism and can therefore clarify the
metabolic signatures of alcohol intake. Such metabolite
profiling approaches are increasingly used also in relation to
alcohol research, but most biomarkers associated with alco-
hol intake have not been related to disease outcomes.14–16
Serum nuclear magnetic resonance (NMR) metabolomics
enables quantitative metabolite profiling of large cohorts
and biobank collections at low costs. This high-throughput
methodology provides detailed lipoprotein subclass profil-
ing, as well as quantification of fatty acids and small mol-
ecules such amino acids, of which many have recently been
linked with the risk for cardiovascular disease and type 2
diabetes.18–22 Associations of these biomarkers with alcohol
intake could therefore elucidate the beneficial and harmful
metabolic processes related to alcohol consumption.
To characterize metabolic signatures of habitual alcohol
consumption, we conducted serum NMR metabolomics of
9778 young adults from three population-based cohorts in
Finland. We further assessed how change in alcohol con-
sumption was accompanied by changes in the systemic
metabolic profile. This clarifies how the detailed metabolic
signature of alcohol intake tracks with changes in alcohol
intake and minimizes influences of confounding. Finally,
we examined the continuous shapes of the metabolic asso-
ciations with alcohol intake to uncover potentially non-
linear relationships with cardiovascular risk markers.
Methods
Study populations
All study participants provided written informed consent,
and study protocols were approved by the local ethics
committees. The study population comprised three
population-based cohorts: the Northern Finland Birth
Cohort of 1966 (NFBC-1966; n¼ 6007 participants in the
31-year field study, among whom n¼ 5711 had metabolic
profiling data available and n¼5025 also data on alcohol
intake);23,24 the FINRISK 1997 study (n¼ 8444 partici-
pants aged 24–74, among whom n¼ 7603 had metabolic
profiling data available and n¼6088 also data on alcohol
intake, n¼ 2900 of these eligible individuals were aged
24–45);24,25 and the Cardiovascular Risk in Young Finns
Study (YFS, n¼ 2283 aged 24–39 at the first time-point of
metabolic profiling, among whom n¼ 2247 had metabolic
profiling data and n¼ 2214 also data on alcohol in-
take).24,26 To minimize reverse causality and to capture as
far as possible physiological rather than pathological asso-
ciations, analyses were restricted to individuals under 46
years of age (n¼10 318 out of 13 227 with metabolic pro-
file and alcohol data available). In addition, pregnant
women (n¼ 270), participants using lipid-lowering medi-
cation (n¼ 17) and individuals reporting alcohol consump-
tion>500 g/week (n¼ 74) were excluded, yielding 9778
participants aged 24–45 for the present meta-analysis of
cross-sectional associations. A subset of 1466 participants
from YFS who were followed up again after 6 years (2001
to 2007) were assessed in longitudinal analyses.24 These
longitudinal analyses were further validated for 1401 YFS
participants with data on alcohol and metabolite levels at
10-year follow-up (2001 to 2011). Body mass index (BMI)
and blood pressure were measured as part of the clinical
examination. Current smoking status and physical activity
index (assessed as metabolic-equivalent of task in NFBC-
1966 and YFS, and as high or low leisure time activity in
FINRISK) were assessed by questionnaires.24 Further de-
tails of the study populations are described in
Supplementary Methods, available as Supplementary data
at IJE online.
Alcohol consumption
Alcohol intake was assessed from questionnaires. In the
NFBC-1966, the average volume of ethanol consumed per
week was estimated from beverage-specific questions on
usual weekly frequency of drinking and usual volume con-
sumed per occasion for beer, cider and long drinks (pre-
mixed ready-to drink cocktails with ethanol volume
approximately 5.5%), light wine, mild, strong or home-
made wine (in 16-cl glasses), and spirits (in 4-cl restaurant
portions).23 In the FINRISK study, the volume of ethanol
consumed in the past week was calculated from beverage-
specific questions on consumption of beer, cider and long
drinks (measured in 0.33-l bottles), wine (in 12-cl glasses)
and spirits (in 4-cl restaurant portions).27 In the YFS, the
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volume of ethanol consumed in the past week was esti-
mated from beverage-specific questions on the volume of
medium beer (4.7%), strong beer (> 4.7%), wine, cider/
long drinks, and spirits consumed. Questions on beer, cider
and long drinks referred to 0.33-l bottles, wine to glasses
and spirits to 4-cl portions.26 The alcohol intake was sum-
marized as volume of ethanol in grams per week for all
three cohorts, with the data harmonized to the volume of
ethanol estimation across the different study question-
naires. Participants with alcohol consumption above 500 g/
week (approximately 99th percentile) were excluded to
avoid the increased likelihood of these values being spuri-
ous due to implausible values.
Metabolic profiling
A high-throughput serum NMR metabolomics platform
was used to quantify 76 circulating lipid and metabolite
measures in the three cohorts.28 This metabolomics plat-
form provides simultaneous quantification of routine lip-
ids, lipid concentrations of 14 lipoprotein subclasses and
major subfractions, and further abundant fatty acids,
amino acids, ketone bodies and gluconeogenesis-related
metabolites in absolute concentration units
(Supplementary Table S1, available as Supplementary data
at IJE online). The platform has been applied extensively
in epidemiological studies;18–22,24,28,29 details of the ex-
perimentation and the analytical repeatability of the bio-
marker quantification have been described
elsewhere.28,30,31 We also analysed 10 additional protein
and hormonal biomarkers measured in at least two co-
horts. These were high-sensitivity C-reactive protein
(CRP), phospholipase activity, gamma glutamyl transfer-
ase (GGT), alanine aminotransferase (ALT), testosterone,
sex-hormone binding globulin (SHBG), adiponectin, lep-
tin, vitamin D and insulin;24 they were measured using
conventional clinical chemistry and mass spectrometry as
described in Supplementary Methods, available as
Supplementary data at IJE online. Inclusion of these add-
itional measures was selected a priori because suspected as-
sociation with alcohol consumption and cardiovascular
risk.
Statistical analysis
Metabolic measures with skewness> 2 were first loge
transformed. All metabolic measures were subsequently
scaled to standard deviation (SD) units separately for each
cohort to enable comparison of association magnitudes.
Due to the correlated nature of the metabolic measures,
more than 95% of the variation in the metabolomic data
in all three cohorts was explained by 32 principal
components. Multiple testing correction therefore ac-
counted for 32 independent tests using the Bonferroni
method, resulting in P< 0.0016 considered statistically
significant.29
Linear regression models were fitted for each metabolic
measure with ethanol intake as the explanatory variable
and the metabolite concentration as the outcome. All mod-
els were adjusted for age and sex. Results were analysed
separately for each cohort and combined using fixed effect
inverse-variance weighted meta-analysis after confirming
the consistency across the three cohorts. Sensitivity ana-
lyses were conducted with additional adjustment for BMI,
smoking and physical activity. Association magnitudes are
presented combined for men and women in the main text
since association magnitudes were generally similar for
both sexes; sex-stratified analyses are presented in the
Supplementary Appendix, available as Supplementary data
at IJE online.
Data on alcohol consumption and metabolite levels
were available for 1466 individuals from YFS at 6-year
follow-up; this was used to examine whether changes in
metabolite concentrations track with changes in alcohol
consumption during follow-up. For these longitudinal ana-
lyses, linear regression models were fitted with 6-year
change in metabolite concentration as the outcome and 6-
year change in ethanol intake as the explanatory variable
with adjustment for age and sex. Baseline and follow-up
metabolite concentrations were standardized to SD units at
baseline, so that cross-sectional and longitudinal associ-
ations are directly comparable. The resemblance between
the overall cross-sectional and longitudinal association pat-
terns was quantified using the R2 goodness-of-fit and the
slope of the linear fit.24 To further validate the consistency
between the cross-sectional and longitudinal associations,
the association patterns were also compared using R2 for
1401 individuals with alcohol and metabolite data at 10-
year follow-up.
The continuous shape of the metabolic associations
with alcohol consumption were examined descriptively
using local quadratic regression fitting, with each smooth-
ing function segment evaluated at 25 points through the
range of ethanol intake. To adjust for age and sex, the ab-
solute concentration of each metabolic measure was first
regressed for age and sex in each cohort and the resulting
residuals were pooled before fitting and rescaled to abso-
lute units. Equivalent analyses were done stratified by sex.
Statistical analyses were conducted using R 3.1.
Results
The study population comprised 9778 young adults
from three Finnish population-based cohorts with
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comprehensive lipid and metabolite profiling data. Clinical
characteristics of the three cohorts are shown in Table 1.
The mean age was 33 years (range 24–45) and 53% of the
participants were women. The median consumption of al-
cohol was around three drinks per week (36 grams of etha-
nol) in all three cohorts. Despite differences in the
questionnaires on alcohol usage relating to usual intake or
consumption during the week preceding the clinical exam-
ination, the distribution of alcohol intake was similar
across the three cohorts (Supplementary Figure S1, avail-
able as Supplementary data at IJE online). Mean concen-
trations of the metabolic measures are listed in
Supplementary Table S1, available as Supplementary data
at IJE online.
Alcohol associations with lipoprotein lipids
Cross-sectional associations of alcohol consumption with
38 lipoprotein and lipid measures are shown in the left panel
of Figure 1; the corresponding associations of change in al-
cohol consumption with change in lipid concentrations are
shown in the right panel. The overall cross-sectional associ-
ation pattern was recapitulated in the longitudinal associ-
ation pattern: the lipids most strongly associated with
alcohol consumption also displayed the highest responsive-
ness to changes in alcohol intake during follow-up.
Increased alcohol consumption was modestly associated
with elevated lipid levels within the largest very-low-density
lipoprotein (VLDL) subclasses, whereas associations with
lipids in the low-density lipoprotein (LDL) subclasses ap-
peared very weak. However, increased alcohol intake was
robustly associated with larger VLDL particle size, whereas
LDL particle size displayed a strong inverse association.
Prominent associations were observed between higher alco-
hol consumption and higher lipid concentrations for all
high-density lipoprotein (HDL) subclasses, particularly for
the medium-sized and small HDL particles. Concomitantly,
the cholesterol and phospholipid concentrations in the HDL
subclasses were robustly elevated in relation to higher alco-
hol intake, whereas triglyceride in HDL were only modestly
elevated. When examining the continuous association
shapes, HDL-related measures were broadly linear or mod-
estly declining in slope across the range of alcohol consump-
tion, whereas more complex continuous association shapes
were observed for the apolipoprotein B-carrying lipids
(Supplementary Figure S2, available as Supplementary data
at IJE online). Here, inverse associations were observed in
the first segment up to 50 g/week, with convex association
curves for men and declining slopes for women. The non-
linear association shapes for these lipid measures partly
mask the associations in the linear models. The pattern
of lipid associations with alcohol intake was highly coherent
across all three cohorts analysed (Supplementary Figure S3,
available as Supplementary data at IJE online). Association
magnitudes in absolute concentration units are listed in
Supplementary Table S1, available as Supplementary data at
IJE online. For example, 100 g higher ethanol intake per
week (corresponding to about eight drink units; 1.29 SD)
was associated with 0.073 mmol/l higher HDL cholesterol.
Alcohol associations with fatty acids
The cross-sectional and longitudinal associations of alco-
hol consumption with circulating fatty acid levels are
Table 1. Clinical characteristics of the study population
Characteristic Northern Finland Birth
Cohort of 1966
FINRISK 1997 study Cardiovascular Risk in
Young Finns study
Number of participants (men/women) 4837 2808 2133
(2414/2423) (1320/1488) (973/1160)
Age (years) 31.2 (0.4) 35.6 (6.2) 31.7 (5.0)
Body mass index (kg/m2) 24.6 (4.1) 25.2 (4.3) 25 (4.4)
Systolic blood pressure (mmHg) 125 (13) 127 (15) 117 (13)
Total cholesterol (mmol/l) 5.1 (1.0) 5.1 (1.0) 5.1 (1.0)
HDL cholesterol (mmol/l) 1.5 (0.4) 1.4 (0.3) 1.3 (0.3)
Triglycerides (mmol/l) 1.0 (0.8–1.4) 1.0 (0.7–1.4) 1.0 (0.8–1.5)
Plasma glucose (mmol/l) 5 (4.7–5.3) 5.0 (4.7–5.3) 4.8 (4.6–5.2)
Insulin (IU/l) 6.7 (4.9–8.9) 7.5 (6.2–9.4) 4.7 (3.3–6.7)
Smoking prevalence (%) 42% 30% 24%
Alcohol usage (g/week) 32.6 (11.5–76.1)a 36.7 (0–93.6)b 39 (0–103)b
Alcohol usage (drinks/week) 2.6 (0.9–6.1)a 3.0 (0.0–7.6)b 3.1 (0.0–8.3)b
Values are mean (SD) and median (interquartile range) for normally distributed and skewed variables, respectively.
aBased on usual volume of ethanol consumed.
bBased on volume of ethanol consumed in the past week.
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shown in Figure 2. The association pattern observed in the
cross-sectional analyses resembled that seen within person
over the 6-year follow-up period, except for omega-3 fatty
acid related measures. Higher alcohol intake was robustly
associated with an increase in the absolute concentrations
of total fatty acids, saturated fatty acids and monounsatu-
rated fatty acids (MUFA). In contrast, absolute concentra-
tions of omega-6 fatty acids were not associated with
alcohol consumption. However, the proportions of fatty
acid levels to total fatty acids are often considered better
Figure 1. Cross-sectional and longitudinal associations between alcohol consumption and lipoprotein lipid measures. Left: cross-sectional associ-
ations of alcohol intake with lipid measures meta-analysed for three cohorts of young adults (n¼ 9778). Right: changes in lipid concentrations associ-
ated with change in alcohol intake after 6-year follow-up for 1466 individuals. All associations were adjusted for age and sex. Error bars denote 95%
confidence intervals. Association magnitudes in absolute concentration units are listed in Supplementary Table S1 and continuous shapes of the
metabolic associations with alcohol intake are shown in Supplementary Figure S2 (available as Supplementary data at IJE online).
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indicators of metabolic risk.18 These measures displayed a
pattern of strongly elevated MUFA ratio with higher alco-
hol consumption, whereas omega-6 fatty acid ratio was
strongly inversely associated with alcohol intake. These
fatty acid associations were linear across the range of alco-
hol intake. The association magnitudes of MUFA ratio
(0.26 SD higher per 100 g weekly ethanol intake, equiva-
lent to 0.90%) and omega-6 proportion (0.23 SD lower
per 100 g weekly ethanol intake, equivalent to 0.87%)
were stronger than those of HDL cholesterol. The associ-
ation of alcohol intake with the proportion of omega-3
fatty acid was only weakly positive cross-sectionally and
inconsistent with this longitudinally.
Alcohol associations with metabolites and
hormones
The cross-sectional and longitudinal associations of alco-
hol consumption with circulating amino acids, gluconeo-
genesis metabolites and various inflammatory and
hormonal measures are show in Figure 3. The strongest as-
sociations for low-molecular-weight metabolites were
observed for glutamine and citrate, both inversely associ-
ated with increased alcohol intake. Whereas most of the
small molecule metabolites were not strongly associated
with alcohol consumption based on the linear models, sub-
tle non-linear association shapes were evident for several
measures, e.g. phenylalanine and glycerol. Higher alcohol
intake was modestly associated with increased levels of
several amino acids, glycolysis and gluconeogenesis-related
metabolites as well as glycoprotein acetyls and C-reactive
protein, markers of chronic inflammation. Higher testos-
terone was associated with alcohol consumption for both
men and women, but an inverse association with SHBG
was only observed for men. Higher alcohol intake was also
associated with the adipokine adiponectin and elevated cir-
culating levels of the liver enzymes GGT and ALT.
Although the power to denote statistical significance was
limited, the changes in metabolite and hormonal concen-
trations associated with 6-year change in alcohol consump-
tion broadly matched with the cross-sectional associations.
Consistency of cross-sectional and longitudinal
association patterns
The resemblance between the overall metabolic association
patterns of alcohol consumption observed cross-sectionally
and longitudinally is illustrated in Figure 4. The associ-
ation magnitudes followed a straight line, with goodness of
fit R2¼ 0.83 (95% confidence intervals 0.77–0.90). The
slope of the linear fit was 0.726 0.04, indicating that each
unit change in alcohol intake was on average accompanied
by a slightly weaker change in the metabolic profile com-
pared with that estimated from the cross-sectional ana-
lyses. The consistency between the cross-sectional and
longitudinal associations was even stronger if only compar-
ing measures associated with alcohol intake at P<0.0016
(R2¼ 0.87). The match of the association patterns was also
similar when cross-sectional and longitudinal associations
were compared only for the same 1466 individuals
Figure 2. Cross-sectional and longitudinal associations between alcohol consumption and fatty acids. Left: cross-sectional associations of alcohol in-
take with circulating fatty acids meta-analysed for three cohorts of young adults (n¼ 9778). Right: changes in fatty acid levels associated with change
in alcohol intake after 6-year follow-up for 1466 individuals. All associations were adjusted for age and sex. Error bars denote 95% confidence
intervals.
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(R2¼ 0.79). Data on metabolic profiling and alcohol in-
take were also available at 10-year follow-up from the
same study population;24 highly coherent results were ob-
tained when the longitudinal and cross-sectional associ-
ation patterns were compared at this extended follow-up
duration (R2¼ 0.77).
Sensitivity analyses
The cross-sectional associations of alcohol intake with
metabolic measures were generally concordant across the
three cohorts (Supplementary Figure S3, available as
Supplementary data at IJE online). Men and women dis-
played a similar overall pattern of metabolic associations
Figure 3. Cross-sectional and longitudinal associations of alcohol consumption with low-molecular-weight metabolites and hormonal measures.
Left: cross-sectional associations of alcohol intake with metabolite and hormonal measures meta-analysed for three cohorts of young adults
(n¼ 9778). Right: changes in metabolite and hormone levels associated with change in alcohol intake after 6-year follow-up for 1466 individuals. All
associations were adjusted for age and sex. Error bars denote 95% confidence intervals.
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with alcohol intake (Supplementary Figure S4, available as
Supplementary data at IJE online). Association magnitudes
in units of 100 g/week were generally stronger for women;
however, Pearson’s correlations between alcohol intake
and the metabolic measures are broadly similar for men
and women because of the higher variation in alcohol in-
take for men (1 SD in ethanol intake ¼ 91 g/week for men
and 52 g/week for women). Although some sex differences
were apparent from the linear modelling, e.g. inverse asso-
ciations for LDL subclasses for women only, these were
mostly related to subtle differences in the continuous asso-
ciation shapes. Surprisingly, adjustment for BMI, smoking
status and physical activity index had little effect on
strength of association (3% attenuation on average;
Supplementary Figure S5, available as Supplementary
data at IJE online). The results were also similar if add-
itional adjustment for baseline alcohol was made in the
longitudinal modelling. All results were essentially un-
altered if excluding the 1388 individuals who ab-
stained from alcohol consumption according to the
questionnaires.
Continuous shape of metabolic associations
with alcohol
The shapes of the metabolic associations as a function of
alcohol consumption are shown for all 86 metabolic meas-
ures in Supplementary Figure S2. The continuous associ-
ation shapes for 12 selected measures are illustrated in
Figure 5. For most of the metabolic measures strongly cor-
related with alcohol intake, the shapes of association were
approximately linear. This is exemplified for MUFA and
omega-6 ratios, relative to total fatty acids, as well as glu-
tamine. Other metabolic measures displayed non-linear as-
sociation shapes, with strong initial increase (e.g. medium
HDL lipids) or decrease (e.g. citrate) that became less steep
at high ranges of alcohol consumption. Omega-3 ratio dis-
played a steep increase followed by a plateau association.
A substantial number of metabolic measures displayed
more complex non-linear associations, as exemplified for
medium VLDL and medium LDL lipid concentrations in
Figure 5. Total triglycerides and LDL cholesterol, respect-
ively, displayed similar shapes as these subclass measures.
U-shaped curves for modest alcohol intake (up to 200 g
Figure 4. Consistency between metabolic associations with alcohol intake at a single time point with the corresponding metabolic changes associ-
ated with 6-year change in alcohol consumption. The resemblance between the overall association patterns was quantified by the linear fit between
the cross-sectional and longitudinal associations with alcohol intake (red dashed line).
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Figure 5. Lipid and metabolite concentrations as a function of alcohol consumption for 12 selected metabolic measures (n¼ 9978). The shaded
curves denote the 95% confidence intervals of the local polynomial regression fits. Associations were adjusted for age, sex and cohort. The continu-
ous shapes of associations for all 86 metabolic measures are shown for men and women in Supplementary Figure S2, available as Supplementary
data at IJE online.
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ethanol/week, approximately two drinks per day; 93% of
the study population in this range) were particularly prom-
inent for men in the case of atherogenic lipid measures
(Supplementary Figure S2). However, similar convex
shapes were observed for both men and women in this
range of alcohol intake for other cardiometabolic risk bio-
markers, such as phenylalanine.
Discussion
Metabolic profiling of almost 10 000 young adults revealed
an intricate pattern of lipid and metabolite associations with
usual alcohol consumption. The molecular signature linked
with alcohol intake cover multiple metabolic pathways,
including lipoprotein subclasses, fatty acid composition, glu-
tamine and citrate regulation and hormonal balance. These
metabolic perturbations comprise a mixture of both favour-
able and adverse effects in relation to cardiovascular disease
and all-cause mortality risk.18,19 The pattern of metabolic
changes accompanying change in alcohol intake at 6-year
follow-up was highly consistent with the metabolic associ-
ation pattern observed at a single time point, suggesting that
the metabolomic signature of alcohol consumption tracks
with long-term changes in alcohol use. Although potential
causal disease relations remain unclear for many of the
metabolic biomarkers, our findings provide improved
understanding of the diverse molecular processes related to
alcohol intake, and may help to clarify the complex medi-
ation between alcohol and cardiovascular risk.
The molecular underpinnings of the apparent cardio-
protective effects of modest alcohol consumption reported
in observational studies remains contentious.3,5,6,26
Numerous observational and interventional studies have
found increased HDL cholesterol and apolipoprotein A-I
levels with higher alcohol intake.3,6,7,32 These lipoprotein
measures serve here as positive controls, along with the
liver enzymes markers, and set the association magnitudes
into perspective: several of the novel metabolic biomarkers
were as strongly associated with alcohol intake as HDL
cholesterol and GGT. Nonetheless, accumulating evidence
argues against a causal role of HDL cholesterol in cardio-
vascular disease,10,11 so other underpinning mediators may
be required to explain potential cardioprotective effects of
moderate alcohol consumption. Medium-sized and small
HDL subclasses displayed the most pronounced associ-
ations, whereas the association slopes for larger HDL sub-
classes levelled off after initial rapid increase. However,
the lipid levels of medium and small HDL are weaker bio-
markers of lower cardiovascular risk than those of large
HDL.18,33 If changes in HDL metabolism due to alcohol
intake are reflecting some underlying cardioprotective
mechanism, then the effects appear less favourable than
assumed by assessing only HDL cholesterol, since this
measure combines subclasses with heterogeneous
associations.
In contrast to HDL cholesterol, the causal atherogenic
role of LDL particles is well established and increas-
ingly clear also for the triglyceride-rich lipoprotein par-
ticles.34 These apolipoprotein B-carrying particles
displayed weak or no association with alcohol intake in
the standard linear models; however, inverse associations
were observed for women in sex-stratified analyses and
men displayed U-shaped associations, with most favour-
able lipid levels observed around 50 grams of ethanol in-
take per week. Similar sex differences have been observed
previously for LDL cholesterol.35,36 Although only a small
fraction of the study population were heavy drinkers, we
recapitulated the anticipated low levels of LDL subclass
lipids at the highest alcohol range. However, LDL particle
size strongly decreased along with increasing alcohol in-
take, and some studies have related this measure to higher
cardiovascular risk.33 These results illustrate how lipopro-
tein subclass profiling may uncover potentially unfavour-
able risk effects missed by routine biomarkers. Further, the
non-linear shapes underline the need to assess continuous
associations with alcohol intake for both established and
emerging biomarkers of cardiometabolic risk. The more fa-
vourable circulating levels of atherogenic lipids observed
for individuals with modest alcohol consumption may
partly contribute to explain the apparent cardioprotective
effect for moderate drinkers; however, the association
magnitudes were too weak to fully attribute the consistent
reports of the U-shaped association with cardiovascular
risk to these lipid measures.
The relation between alcohol intake and the fatty acid
balance revealed a mixed set of associations, with mostly
adverse aberrations in terms of biomarkers for cardiovas-
cular risk.18 Subtle sex differences and non-linear associ-
ation shapes contributed to the complex picture, e.g. for
omega-3 fatty acid ratio. MUFA ratio displayed the stron-
gest association with alcohol intake among all the 86 meta-
bolic measures analysed. Contrary to the dietary intake of
this measure, higher circulating MUFA ratio is a biomarker
of higher cardiovascular and diabetes risk.18,20 Likewise,
the robust association of alcohol intake with lower propor-
tion of omega-6 fatty acids is also related to higher cardio-
metabolic risk.18,20,37 Our findings are consistent with
much smaller studies on men at high risk for cardiovascu-
lar disease or suffering from alcohol dependence.38,39 The
prominent fatty acid associations were essentially linear
across the entire range of alcohol consumption and were
corroborated by the longitudinal analyses. Although the
causality of these fatty acids remains unclear, the primarily
adverse changes in these emerging risk markers indicate
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also unfavourable metabolic aberrations with modest alco-
hol consumption.
Recent metabolic profiling studies have linked several
circulating amino acids and other small molecules with the
risk for cardiovascular disease, type 2 diabetes and all-
cause mortality.18,19,21,40,41 Dietary determinants of these
circulating biomarkers remain poorly understood. In the
present analyses, only few low-molecular-weight metabol-
ites were strongly associated with alcohol intake. The most
prominent associations were for citrate and glutamine,
both strongly inversely associated with alcohol intake but
otherwise weakly correlated with established risk fac-
tors.19,24 Our results are supported by a smaller metabolo-
mics study of alcohol intake in Japanese men.16 Higher
citrate levels have been linked with modestly lower risk for
cardiovascular disease,18 but simultaneously with higher
risk of all-cause mortality.19 The biological underpinnings
of citrate’s links with disease remain elusive. Higher circu-
lating glutamine is associated with lower risk for cardio-
vascular disease18 and type 2 diabetes.21,40 Glutamine and
citrate are connected via the citric acid cycle and both me-
tabolites play critical roles at the centre of cancer cell me-
tabolism.42,43 Multiple other metabolites and hormones
also displayed associations with alcohol intake; however,
further investigations are required to clarify whether these
molecular perturbations could arise as a combined effect of
alcohol intake on multiple metabolic pathways.
Our study has both strengths and limitations. The large
sample size provides robust evidence for many novel meta-
bolic markers of alcohol consumption, in particular since
results were coherent across the three cohorts despite dif-
ferences between the measures of alcohol intake. Although
our study was conducted solely in the homogeneous
Finnish population, many of the strongest metabolic bio-
markers have been related to alcohol intake in smaller
cross-sectional studies of populations with other ethnic-
ities.14,16,39 Observational studies on alcohol consumption
are susceptible to confounding and reverse causation.3,5 By
design, all study participants were young and relatively
healthy, which minimizes influences of reverse causality.
The associations were also essentially unaltered when
excluding non-drinkers; the results are thus unlikely to be
influenced by those who may have stopped drinking for
health reasons. All results were similar when adjusting for
adiposity, smoking and physical activity, suggesting lim-
ited confounding by these risk factors clustering with alco-
hol intake. The lack of association with leptin, and the
distinct metabolic association pattern from that caused by
elevated BMI24, make it implausible that the metabolic
perturbations would be mediated via effects of alcohol on
adiposity. However, dietary composition may potentially
confound the results.
The consistency of the cross-sectional and longitudinal
association patterns helps exclude influence of unmeasured
confounders that are fixed individual characteristics; how-
ever, we acknowledge that the longitudinal associations re-
main susceptible to other types of confounding.
Nevertheless, missingness and inaccurate reporting of alco-
hol intake may still bias the reported point estimates, and
likely underestimate the magnitude of the metabolic associ-
ations. The majority of study participants consumed alco-
hol only in low or moderate amounts, which prevents
inferences about the metabolic associations with heavy al-
cohol consumption. Metabolomics of interventional stud-
ies could clarify whether the diverse metabolic changes
arise due to short-term effects of alcohol intake or chronic
exposure, for instance mediated via impaired liver func-
tion. Further studies may also characterize the metabolic
effects of binge drinking, specific beverage types and
whether the circulating markers of alcohol consumption
could benefit identification of individuals at risk for alco-
holic liver disease.
In conclusion, metabolic profiling of three large
population-based cohorts identified novel metabolic
markers for dose-dependent alcohol intake. The detailed
metabolic phenotyping further clarified the association
shapes for numerous established biomarkers related to al-
cohol and cardiometabolic risk. The metabolic signature of
alcohol consumption included molecular perturbations
linked with both higher and lower cardiovascular risk.
Many metabolic measures displayed an optimum level at
modest alcohol intake. The striking match between the
overall cross-sectional and longitudinal association pat-
terns provides evidence in support of the metabolic
changes arising, at least partly, due to alcohol consump-
tion. Comprehensive metabolic profiling in these large co-
horts thus elucidated the metabolic influences of alcohol
consumption and clarified the double-edged relation be-
tween alcohol and cardiometabolic biomarkers.
Supplementary Data
Supplementary data are available at IJE online.
Funding
This study was supported by Strategic Research Funding from the
University of Oulu, Sigrid Juselius Foundation, Academy of Finland
(grant numbers 250422, 139635), Novo Nordisk Foundation, Paavo
Nurmi Foundation, Yrjo¨ Jahnsson Foundation, Emil Aaltonen
Foundation, Finnish Diabetes Research Foundation, Finnish
Foundation for Cardiovascular Research and UK Medical Research
Council via the University of Bristol Integrative Epidemiology Unit
(MC_UU_12013/1 and MC_UU_12013/5). The Cardiovascular Risk
in Young Finns Study is supported by Academy of Finland (286284,
1504 International Journal of Epidemiology, 2016, Vol. 45, No. 5
134309, 126925, 121584, 124282, 129378, 117787, 41071), the
Social Insurance Institution of Finland, Kuopio, Tampere and Turku
University Hospital Medical Funds, Juho Vainio Foundation, Paavo
Nurmi Foundation, Finnish Foundation of Cardiovascular Research,
Finnish Cultural Foundation, Emil Aaltonen Foundation and Yrjo¨
Jahnsson Foundation. The Northern Finland Birth Cohort has
received financial support from Academy of Finland, University
Hospital Oulu, Biocenter Oulu, University of Oulu, the European
Commission [EURO-BLCS, Framework 5 award QLG1-CT-2000-
01643, ENGAGE project and grant agreement HEALTH-F4-2007-
201413, EurHEALTHAgeing (277849), European Regional
Developmental Fund], EU H2020-PHC-2014 (grant no. 633595),
NHLBI grant 5R01HL087679-02 through the STAMPEED pro-
gramme (1RL1MH083268 01), NIH/NIMH (5R01MH63706:02),
Stanley Foundation, UK Medical Research Council and Wellcome
Trust.
Conflict of interest: P.W., A.J.K., P.S. and M.A.K. are shareholders
of Brainshake Ltd, a company offering NMR-based metabolite
profiling. P.W., Q.W., M.T., T.T., A.J.K. and P.S. report employ-
ment relation with Brainshake Ltd. No other authors reported
disclosures.
References
1. GBD 2013 Risk Factors Collaborators. Global, regional, and na-
tional comparative risk assessment of 79 behavioural, environ-
mental and occupational, and metabolic risks or clusters of risks
in 188 countries, 1990–2013: a systematic analysis for the Global
Burden of Disease Study 2013. Lancet 2015;386:2287–323.
2. World Health Organization. Global Status Report on Alcohol a
Health 2014. Geneva: WHO, 2014.
3. O’Keefe JH, Bybee KA, Lavie CJ. Alcohol and cardiovascular
health: the razor-sharp double-edged sword. J Am Coll Cardiol
2007;50:1009–14.
4. Bergmann MM, Rehm J, Klipstein-Grobusch K et al. The associ-
ation of pattern of lifetime alcohol use and cause of death in the
European Prospective Investigation into Cancer and Nutrition
(EPIC) study. Int J Epidemiol 2014;42:1772–90.
5. Holmes MV, Dale CE, Zuccolo L et al. Association between
alcohol and cardiovascular disease: Mendelian randomisation ana-
lysis based on individual participant data. BMJ 2014;349:g4164.
6. Gepner Y, Golan R, Harman-Boehm I et al. Effects of initiating
moderate alcohol intake on cardiometabolic risk in adults with
type 2 diabetes.Ann InternMed 2015;163:569–79.
7. Brien SE, Ronksley PE, Turner BJ, Mukamal KJ, Ghali WA.
Effect of alcohol consumption on biological markers associated
with risk of coronary heart disease: systematic review and meta-
analysis of interventional studies. BMJ 2011;342:d636.
8. Taylor AE, Lu F, Carslake D et al. Exploring causal associations
of alcohol with cardiovascular and metabolic risk factors in a
Chinese population using Mendelian randomization analysis. Sci
Rep 2015;5:14005.
9. Cho Y, Shin S-Y, Won S, Relton CL, Davey Smith G, Shin M-J.
Alcohol intake and cardiovascular risk factors: A Mendelian ran-
domisation study. Sci Rep 2015;5:18422.
10. Schwartz GG, Olsson AG, Abt M et al. Effects of dalcetrapib in
patients with a recent acute coronary syndrome. N Engl J Med
2012;367:2089–99.
11. Voight BF, Peloso GM, Orho-Melander M et al. Plasma HDL
cholesterol and risk of myocardial infarction: a mendelian ran-
domisation study. Lancet 2012;380:572–80.
12. Sabater-Lleal M, Huang J, Chasman D et al. Multiethnic meta-
analysis of genome-wide association studies in > 100 000 sub-
jects identifies 23 fibrinogen-associated loci but no strong evi-
dence of a causal association between circulating fibrinogen and
cardiovascular disease.Circulation 2013;128:1310–24.
13. Yaghootkar H, Lamina C, Scott R et al. Mendelian randomiza-
tion studies do not support a causal role for reduced circulating
adiponectin levels in insulin resistance and type 2 diabetes.
Diabetes 2013;62:3589–98.
14. Zheng Y, Yu B, Alexander D, Steffen LM, Nettleton JA,
Boerwinkle E. Metabolomic patterns and alcohol consumption
in African Americans in the Atherosclerosis Risk in
Communities Study. Am J Clin Nutr 2014;99:1470–78.
15. Jaremek M, Yu Z, Mangino M et al. Alcohol-induced metabolo-
mic differences in humans. Transl Psychiatry 2013;3:e276.
16. Harada S, Takebayashi T, Kurihara A et al. Metabolomic profil-
ing reveals novel biomarkers of alcohol intake and alcohol-
induced liver injury in community-dwelling men. Environ
Health Prev Med 2016;21:18–26.
17. Mukamal KJ, Mackey RH, Kuller LH et al. Alcohol consump-
tion and lipoprotein subclasses in older adults. J Clin Endocrinol
Metab 2007;92:2559–66.
18. Wu¨rtz P, Havulinna AS, Soininen P et al. Metabolite profiling
and cardiovascular event risk: a prospective study of 3
population-based cohorts.Circulation 2015;131:774–85.
19. Fischer K, Kettunen J, Wu¨rtz P et al. Biomarker profiling by nu-
clear magnetic resonance spectroscopy for the prediction of all-
cause mortality: An observational study of 17,345 persons.
PLoSMed 2014;11:e1001606.
20. Mahendran Y, Cederberg H, Vangipurapu J et al. Glycerol and
fatty acids in serum predict the development of hyperglycemia and
type 2 diabetes in Finnish men.Diabetes Care 2013;36:3732–38.
21. Stancakova A, Civelek M, Saleem NK et al. Hyperglycemia and a
common variant of GCKR are associated with the levels of eight
amino acids in 9,369 Finnish men. Diabetes 2012;61:1895–902.
22. Wu¨rtz P, Raiko JR, Magnussen CG et al. High-throughput quan-
tification of circulating metabolites improves prediction of sub-
clinical atherosclerosis. Eur Heart J 2012;33:2307–16.
23. J€arvelin M-R, Sovio U, King V et al. Early life factors and blood
pressure at age 31 years in the 1966 northern Finland birth co-
hort. Hypertension 2004;44:838–46.
24. Wu¨rtz P, Wang Q, Kangas AJ et al. Metabolic signatures of adi-
posity in young adults: Mendelian randomization analysis and
effects of weight change. PLoSMed 2014;11:e1001765.
25. Vartiainen E, Laatikainen T, Peltonen M et al. Thirty-five-year
trends in cardiovascular risk factors in Finland. Int J Epidemiol
2010;39:504–18.
26. Juonala M, Viikari JSA, K€aho¨nen M et al. Alcohol consumption
is directly associated with carotid intima–media thickness in
Finnish young adults.Atherosclerosis 2009;204:e93–e98.
27. Poikolainen K, Vartiainen E. Determinants of gamma-
glutamyltransferase: positive interaction with alcohol and body
mass index, negative association with coffee. Am J Epidemiol
1997;146:1019–24.
International Journal of Epidemiology, 2016, Vol. 45, No. 5 1505
28. Soininen P, Kangas AJ, Wu¨rtz P, Suna T, Ala-Korpela M.
Quantitative serum nuclear magnetic resonance metabolomics in
cardiovascular epidemiology and genetics. Circ Cardiovasc
Genet 2015;8:192–206.
29. Kujala UM, M€akinen V-P, Heinonen I et al. Long-term leisure-
time physical activity and serum metabolome. Circulation
2013;127:340–48.
30. Soininen P, Kangas AJ, Wu¨rtz P et al. High-throughput serum
NMR metabonomics for cost-effective holistic studies on sys-
temic metabolism.Analyst 2009;134:1781.
31. Kettunen J, Demirkan A, Wu¨rtz P et al. Genome-wide study for
circulating metabolites identifies 62 loci and reveals novel sys-
temic effects of LPA. Nat Commun 2016;7:11122.
32. Brinton EA. Effects of ethanol intake on lipoproteins. Curr
Atheroscler Rep 24;4:108–14.
33. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM.
Lipoprotein particle profiles by nuclear magnetic resonance com-
pared with standard lipids and apolipoproteins in predicting in-
cident cardiovascular disease in women. Circulation
2009;119:931–39.
34. Do R, Willer CJ, Schmidt EM et al. Common variants associated
with plasma triglycerides and risk for coronary artery disease.
Nat Genet 2013;45:1345–52.
35. Whitfield JB, Heath AC, Madden PAF, Pergadia ML,
Montgomery GW, Martin NG. Metabolic and biochemical ef-
fects of low-to-moderate alcohol consumption. Alcoholism Clin
Exp Res 2013;37:575–86.
36. Tolstrup JS, Gronbaek M, Nordestgaard BG. Alcohol intake,
myocardial infarction, biochemical risk factors, and alcohol de-
hydrogenase genotypes. Circ Cardiovasc Genet 2009;2:507–14.
37. Wu JHY, Lemaitre RN, King IB et al. Circulating omega-6 poly-
unsaturated fatty acids and total and cause-specific mortality:
the Cardiovascular Health Study. Circulation
2014;130:1245–53.
38. Simon JA, Fong J, Bernert JT, Browner WS. Relation of smoking
and alcohol consumption to serum fatty acids. Am J Epidemiol
1996;144:325–34.
39. Teubert A, Thome J, Bu¨ttner A, Richter J, Irmisch G. Elevated
oleic acid serum concentrations in patients suffering from alco-
hol dependence. J Mol Psychiatry 2013;1:13.
40. Cheng S, Rhee EP, Larson MG, et al. Metabolite profiling identi-
fies pathways associated with metabolic risk in humans.
Circulation 2012;125:2222–2231.
41. Roberts LD, Gerszten RE. Toward new biomarkers of cardiome-
tabolic diseases.Cell Metab 2013;18:43–50.
42. Wise DR, Ward PS, Shay JES et al. Hypoxia promotes isocitrate
dehydrogenase-dependent carboxylation of a-ketoglutarate to
citrate to support cell growth and viability. Proc Natl Acad Sci U
S A 2011;108:19611–16.
43. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer:
cell biology, physiology, and clinical opportunities. J Clin Invest
2013;123:3678–3684.
1506 International Journal of Epidemiology, 2016, Vol. 45, No. 5
